Press

2024-02-23

Kancera resolves on a rights issue of approximately SEK 121.9 million

The board of directors of Kancera AB (”Kancera” or the ”Company”), has today, based on the issue authorization from the annual general meeting held on May 25, 2023, resolved on a new share issue with preferential rights for the...

Read More
2024-02-23

Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...

Read More
2023-12-20

Kancera reports positive top line results from the FRACTAL study

Kancera AB (publ) today reports the top line results from the FRACTAL study, a double-blinded placebo-controlled, explorative phase IIa study of Kancera’s fractalkine blocker KAND567 in high-risk ST-elevation myocardial infarction (STEMI) patients undergoing acute percutaneous coronary intervention (PCI). The...

Read More
2023-11-17

Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the third quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 9,2 million (SEK 8,7 million). Operating income for the third quarter amounted to SEK...

Read More
2023-10-13

Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023

Kancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.

Read More
2023-08-18

Kancera provides operational update in connection with release of financial interim report for second quarter

In connection with the release of the financial interim report for the second quarter of 2023, Kancera AB (publ) provides an operational update and announces that top line results from the ongoing FRACTAL study are expected to be presented...

Read More
2023-08-18

Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the second quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 16.5 million (SEK 14.7 million). Operating income for the second quarter amounted to SEK...

Read More
2023-05-26

Kancera appoints Peter Selin as new Chief Executive Officer

Kancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as Executive Vice President and Chief Scientific Officer (CSO).

Read More
2023-05-19

Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

The period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...

Read More
2022-10-20

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).

Read More